Quantum BioPharma's Lucid-MS Advances: A New Era in Myelin Protection for MS
August 19, 2026 — Quantum BioPharma's Lucid-MS, a first-in-class myelin-protecting therapy for MS, gets FDA clearance for Phase 2 trials. Learn how this could change MS treatment.